Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 8/20 | 0.37 |
| ▸ | CCNH | P51946 | 7/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.36 |
| ▸ | CCNK | O75909 | 7/20 | 0.36 |
| ▸ | CDK9 | P50750 | 7/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.36 |
| ▸ | CDK2 | P24941 | 6/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901501 | 0.80 | CDK7 (0.41) | IDH2PRKCZCDK7CCNHMNAT1 | |
| SCHEMBL9901234 | 0.70 | IL1B (0.42) | IDH2CHEK2PRKCZPRKD2 | |
| SCHEMBL30259588 | 0.69 | KDM4E (0.61) | IDH2PRKCZCDK7CCNHMNAT1 | |
| SCHEMBL26604076 | 0.69 | IDH2 (0.50) | IDH2PRKCZCDK7CCNHMNAT1 | |
| SCHEMBL26604080 | 0.69 | IDH2 (0.50) | IDH2PRKCZCDK7CCNHMNAT1 | |
| SCHEMBL23197829 | 0.67 | IDH2 (0.45) | IDH2PRKCZMAPK3CDK7CCNH | |
| SCHEMBL31197278 | 0.67 | CDK7 (0.43) | IDH2PRKCZCDK7CCNHMNAT1 | |
| SCHEMBL269583 | 0.66 | CCNK (0.50) | CDK7CCNHMNAT1CCNT1CCNK | |
| SCHEMBL268925 | 0.66 | CCNK (0.50) | CDK7CCNHMNAT1CCNT1CCNK | |
| SCHEMBL9900746 | 0.66 | PRKCZ (0.43) | CHEK2PRKCZPRKD2CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | claimed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | IDH2 82/4885CHEK2 1150/4885PRKCZ 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.